In 2018, Hussain I et al. proposed the designation of a distinctive syndrome due to heterozygous LMNA p.T10I variants, called generalised lipodystrophy-associated progeroid syndrome, considering the unique and relatively homogeneous clinical features of this disorder in comparison with the previously reported APS. The gene discussed is LMNA; the disease is autoimmune polyendocrinopathy.